Melbourne-based biopharmaceutical giant Telix Pharmaceuticals announced today its plans for an initial public offering in the United States and listing on the Nasdaq Global Market.
However, the company did not disclose the number of American Depositary Shares (ADS) to be issued or a timeline for the listing.
In an ASX announcement, the company said a registration statement relating to Telix’s ADSs to be sold in the proposed offering is expected to be filed with the US Securities and Exchange Commission.
“No final decision has been made in respect of the offering or Nasdaq listing and there can be no assurance as to the occurrence, timing, pricing and/or completion of such an offering or listing,” the Australian company said.
Telix’s noted that its ordinary shares will remain listed on the Australian Securities Exchange.
Telix’s shares jumped following the announcement on Friday, Reuters said in a news report.
The company’s shares reportedly surged by 4.1 per cent, reaching $9.92 per share, marking its most significant daily gain since 12 December 2023.
